Navigation Links
Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO
Date:5/28/2009

MELBOURNE, Australia, May 28 /PRNewswire-FirstCall/ -- Cytopia Limited (ASX: CYT) announced that it will present preliminary data from its Phase I clinical trial of orally administered CYT997, at the Annual Meeting of the American Society of Clinical Oncologists (ASCO), in Orlando, Florida, USA.

Dr Alessandra Francesconi, one of the clinical investigators for the program, will be presenting the poster in the Developmental Therapeutics - Vascular Targeting poster session on Saturday 30th May from 8:00 AM to 12:00 PM (US EST), Level 2, West Hall C.

The poster entitled "Phase I evaluation of orally-administered CYT997, a novel cytotoxic vascular-disrupting agent, in patients with advanced cancer" details safety, tolerability and preliminary activity findings from this study, which concluded in February 2009. CYT997 is currently undergoing further clinical investigation in Phase II studies in relapsed glioblastoma multiforme and multiple myeloma.

Enquiries


    Dr. Gregg Smith                            Mr. Andrew Macdonald
    Director, Drug Development and Operations  Chief Executive Officer
    T: +61 3 9208 4234                         T: +61 3 9208 4232
    gregg.smith@cytopia.com.au                 andrew.macdonald@cytopia.com.au

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and drug development through subsidiaries based in Australia and the USA and specializes in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.

The company's lead drug candidate is CYT997, a vascular disrupting agent (VDA) for the treatment of various cancers, which is currently being trialed in Phase II clinical studies. Cytopia is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in mid 2009.

Website: www.cytopia.com.au


'/>"/>
SOURCE Cytopia Limited
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cytopia Presentation on VDA CYT997 at AACR Conference
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
6. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
7. Phase III Trial Finds Pharmaxis Bronchitol Effective
8. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
9. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
10. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
11. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 /PRNewswire/ ... London (ICR) and University of ... tool to risk-stratify patients with multiple myeloma (MM), in a ... . The University of Leeds is ... Myeloma UK, and ICR will perform the testing services to ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive ... a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM ... firm for the life sciences and healthcare industries, announces a presentation by Subbu ... , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree ... products targeting the needs of consumers who are incorporating medical marijuana into their ... Phoenix, Arizona. , As operators of two successful Valley dispensaries, The Giving Tree’s ...
Breaking Biology Technology:
(Date:10/4/2017)... , Oct. 4, 2017  GCE Solutions, a global clinical research ... and document anonymization solution on October 4, 2017. Shadow is designed ... to comply with policy 0070 of the European Medicines Agency (EMA) ... ... Solutions ...
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017  IBM ... in dairy research, today announced a new collaboration using ... the chances that the global milk supply is impacted ... project, Cornell University has become the newest academic institution ... Chain, a food safety initiative that includes IBM Research, ...
(Date:5/6/2017)... , May 5, 2017 RAM ... announced a new breakthrough in biometric authentication based ... quantum mechanical properties to perform biometric authentication. These new ... semiconductor material created by Ram Group and its ... entertainment, transportation, supply chains and security. Ram Group ...
Breaking Biology News(10 mins):